Pepgen announces christopher ashton, phd, to retire from its board of directors

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that christopher ashton, phd, intends to retire from the board of directors effective september 30, 2024. dr. ashton has served on pepgen's board of directors since december 2019 and was a member of the audit and compensation committees.
PEPG Ratings Summary
PEPG Quant Ranking